最近的观察结果表明，与使用标准抗血小板药物治疗方案的非DM患者相比，DM中达到的血小板抑制作用不足而导致的。
Recent observations suggest that this may be in part due to inadequate platelet inhibition achieved in DM patients compared to non-DM using standard antiplatelet treatment regimens.
结果表明，GMP- 140对AMI的诊断、病情严重程度的评估都有帮助，并为选用抗血小板药物治疗提供了客观依据。
The results indicate that GMP-140 can be used to help the diagnosis of AMI, to assess the severity of AMI and provide an objective index to administer anti-platelet agents.
最大的变化是抗血小板药物的使用率增加，比如双重抗血小板治疗以及抗凝治疗。
The biggest change has been in the increased use of international therapy and anti-platelet agents as dual anti-platelet therapy, and antithrombotics.
接受药物洗脱支架的患者长病变和复杂病变比接受裸金属支架的患者多，而且接受双重抗血小板治疗1年的可能性较大。
DES recipients had longer and more complex lesions than BMS recipients and also were more likely to be receiving dual antiplatelet therapy at 1 year.
目的：探讨下肢深静脉血栓介入治疗中形成急性血栓，应用新型抗血小板药物替罗非班的临床价值。
Objective: To study the application value of neotype antiplatelet drug tirofiban in the interventional therapy of lower extremity deep venous thrombosis after acute thrombosis was formed.
我觉得，三重治疗并不能解决问题，而应该选择其他可选择的抗血小板药物。
In my opinion, it is not with triple therapy that we can solve this problem but with alternative antiplatelet agents.
因此抗血小板药物在ACS治疗中有着重要的地位。
Antiplatelet agents play an important role in the treatment of ACS.
该病例代表了不能确诊的或保守治疗髂腰肌撞击后的一个潜在的重要的并发症，尤其在服用抗凝药物或抗血小板药物的病人中。
This case represents a potentially important complication of undiagnosed or conservatively managed iliopsoas impingement, particularly in patients taking anticoagulants or antiplatelet medications.
目前，对于接受药物洗脱支架的患者，我们尝试维持双重抗血小板治疗在一年以上，因为我们非常关注晚期支架内血栓形成的可能性。
Right now, we try to keep dual anti-platelet therapy going for up to one year in patients who have a drug-eluting stent because we are very concerned about the possibility of late-stent thrombosis.
氯吡格雷是一种抗血小板药物，是新型二磷酸腺苷受体拮抗剂，已广泛应用于急性冠脉综合征和经皮冠状动脉介入治疗的抗血栓治疗。
Clopidogrel is a kind of drug to resistant platelet, it is a new ADP receptor resistant. It has been used in acute coronary syndrome and percutaneous coronary intervention patients widely.
抗血小板药物通过阻断不同的作用位点抑制血小板聚集，从而达到预防及治疗血栓性疾病的作用。
They can through different sites of action blocking platelet gathered, so as to achieve the role of prevention and treatment of thrombotic disorders.
心血管事件的二级预防：抗血小板治疗药物越“先进”越完美吗？
Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events: More "Advanced" Drug, More Perfect?
心血管事件的二级预防：抗血小板治疗药物越“先进”越完美吗？
Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events: More "Advanced" Drug, More Perfect?
应用推荐